Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
Journal
American journal of kidney diseases : the official journal of the National Kidney Foundation
Journal Volume
82
Journal Issue
1
Date Issued
2023-07
Author(s)
Yi, Tae Won
Smyth, Brendan
Di Tanna, Gian Luca
Arnott, Clare
Cardoza, Kathryn
Kang, Amy
Pollock, Carol
Agarwal, Rajiv
Bakris, George
Charytan, David M
de Zeeuw, Dick
Heerspink, Hiddo J L
Neal, Bruce
Wheeler, David C
Cannon, Christopher P
Zhang, Hong
Zinman, Bernard
Perkovic, Vlado
Levin, Adeera
Mahaffey, Kenneth W
Jardine, Meg
Abstract
It is unclear whether the effect of canagliflozin on adverse kidney and cardiovascular events in those with diabetic kidney disease varies by age and sex. We assessed the effects of canagliflozin among age group categories and between sexes in the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study.
Subjects
Diabetic kidney disease; age; canagliflozin; cardiovascular outcomes; chronic kidney disease; diabetes; kidney outcomes; sex; sodium/glucose cotransporter 2 inhibitors
Type
journal article